Levosimendan as a Rescue Drug in Experimental Propranolol-Induced Myocardial Depression: A Randomized Study

Annals of Emergency Medicine

Volumn 54, Issue 6, 2009, Pages

  Leppikangas, Heli ^b   Ruokonen, Esko ^a   Rutanen, Juha ^a   Kiviniemi, Vesa ^c   Lindgren, Leena ^b   Kurola, Jouni ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; DOBUTAMINE; LACTIC ACID; LEVOSIMENDAN; PLACEBO; PROPRANOLOL; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG INTOXICATION; HEART DISEASE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE PRESSURE; HEART OUTPUT; HEART STROKE VOLUME; INOTROPISM; MEAN ARTERIAL PRESSURE; MYOCARDIAL DEPRESSION; NONHUMAN; OXYGEN SATURATION; PRIORITY JOURNAL;

EID: 70449703291     PISSN: 01960644     EISSN: 10976760     Source Type: Journal    
DOI: 10.1016/j.annemergmed.2009.06.512     Document Type: Article

References (23)

1. Bronstein A.C., Spyker D.A., Cantilena Jr. L.R., et al., American Association of Poison Control Centers. 2007 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 25th annual report. Clin Toxicol (Phila) 46 (2008) 927-1057
2. DeWitt C.R., and Waksman J.C. Pharmacology, pathophysiology and management of calcium channel and beta-blocker toxicity. Toxicol Rev 23 (2004) 223-238
3. Newton C.R.H., Delgado J.H., and Gomez H. Calcium and beta receptor antagonist overdose: a review and update of pharmacological principles and management. Semin Respir Crit Care Med 23 (2002) 19-25
4. Sandroni C., Cavallaro F., Addario C., et al. Successful treatment with enoximone for severe poisoning with atenolol and verapamil: a case report. Acta Anesth Scand 48 (2004) 790-792
5. Sainz R., Berestrand W., Williams W., et al. Atenolol-induced cardiovascular collapse treated with haemodialysis. Crit Care Med 19 (1991) 116-118
6. Pfaender M., Casetti P.G., Azzolini M., et al. Successful treatment of massive atenolol and nifedipine overdose with CVVHDF. Minerva Anestesiol 74 (2008) 97-100
7. Haikala H., Kaivola J., Nissinen E., et al. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 27 (1995) 1859-1866
8. Sorsa T., Heikkinen S., Abbott M.B., et al. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem 276 (2001) 9337-9343
9. Givertz M.M., Andreou C., Conrad C.H., et al. Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force-frequency and relaxation frequency relationships. Circulation 115 (2007) 1218-1224
10. Sonntag S., Sundberg S., Lehtonen L.A., et al. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol 43 (2004) 2177-2182
11. Pagel P.S., Harkin C.P., Hettrick D.A., et al. Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs. Anesthesiology 81 (1994) 974-987
12. Pataricza J., Hohn J., Petri A., et al. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol 52 (2000) 213-217
13. Haikala H., Nissinen E., Etemadzadeh E., et al. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 25 (1995) 794-801
14. Morelli A., De Castro S., Teboul J.-L., et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 31 (2005) 638-644
15. Hasenfuss G., Pieske B., Castell M., et al. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 98 (1998) 2141-2147
16. Lochner A., Colesky F., and Genade S. Effect of a calcium-sensitizing agent, levosimendan, on the postcardioplegic response of the myocardium. Cardiovasc Drugs Ther 14 (2000) 271-281
17. Packer M., Carver J.R., Rodeheffer R.J., et al. Effects of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325 (1991) 1468-1475
18. + channel in rat arterial myocytes. Eur J Pharmacol 333 (1997) 249-259
19. Michaels A.D., McKeown B., Kostal M., et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation 111 (2005) 1504-1509
20. Slawsky M.T., Colucci W.S., Gottlieb S.S., et al. ; for the Study Investigators. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 102 (2000) 2222-2227
21. Yokoshiki H., and Sperelakis N. Vasodilating mechanisms of levosimendan. Cardiovasc Drugs Ther 17 (2003) 111-113
22. Oh Y.J., Lee J.H., Kim J.Y., et al. The haemodynamic effects of propranolol and atenolol medication on dobutamine infusion in patients with coronary artery obstructive disease. J Int Med Res 33 (2005) 329-336
23. Follath F., Cleland J.G.F., Just H., et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet 360 (2002) 196-202